A Phase 3 interventional study of Triptorelin pamoate 15mg in Central Precocious Puberty, sponsored by Ipsen. Completed at 7 sites in China. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2024-08-01.
Sponsored by Ipsen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Puberty, Precocious with a site in China — 4 open to participants now, 4 under way, 1 of them phase 3. Puberty, Precocious · China.
Among the 17 studies in Puberty, Precocious with a site in China, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 8th registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →4 of the 17 studies in Puberty, Precocious with a site in China are open now. Recruiting first, the newest first:
Children's Hospital of Fudan University · Sites in China
Ages 4–9 · Women only
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 6–12
Children's Hospital of Fudan University · Sites in China
Ages 5–9 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 2–10
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: Up to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2021.
This study's enrollment of 32 is below the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 94 across the 13 interventional studies, 835 across the 4 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 17 have an industry lead sponsor. The 7 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Ipsen has 4 studies filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
2 of the studies in Puberty, Precocious with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06510764Phase 3Children's Hospital of Fudan UniversityA Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty | 2027-07-01 |
| NCT06487143Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityEfficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Puberty, Precocious with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research was to confirm the effectiveness and safety of the study drug, Triptorelin pamoate 15mg 3-month formulation, in a Chinese population of Central Precocious Puberty (CPP) children.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Triptorelin was injected at day 1 and month 3. If participants were willing to enter the extension phase, two additional Triptorelin injections were given at month 6 and month 9.
Drug: Triptorelin pamoate 15mg
Intramuscular injection (IM)
Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation
The LH suppression was defined as stimulated peak LH ≤3 International Units/Liter (IU/L). The GnRH stimulation test was performed by using an intravenous (IV) injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels.
Time frame: At Month 3
Change From Baseline in Basal LH and Follicle-Stimulating Hormone (FSH) Serum Levels
Basal LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the value for LH and FSH levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 3, 6, 9 and 12
Percentage of Participants With LH Suppression After GnRH Stimulation
A synthetic GnRH (gonadorelin) was used for gonadotrophin stimulation. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) (±5 minutes at each timepoint) after a single IV injection of gonadorelin. A suppressed LH response to GnRH stimulation test was defined as peak LH ≤3 IU/L among the 4 timepoints T0, T30, T60 and T90).
Time frame: At Months 6 and 12
Change From Baseline in Peak LH and FSH Level After GnRH Stimulation
A synthetic GnRH was used for gonadotrophin stimulation. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) (±5 minutes at each timepoint) after a single IV injection of gonadorelin. The FSH response to GnRH stimulation was the peak FSH level among the 4 timepoints (T0, T30, T60 and T90). The LH response to GnRH stimulation test was defined as peak LH ≤3 IU/L among the 4 timepoints T0, T30, T60 and T90). Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 3, 6 and 12
Percentage of Participants With Prepubertal Levels of Sex Steroids
Prepubertal sex steroids assessment included estradiol in female participants and testosterone in male participants. Prepubertal sex steroids levels were defined as: estradiol ≤20 picogram (pg)/milliliter (mL) in female participants and testosterone ≤0.3 nanogram (ng)/mL in male participants.
Time frame: At Months 3, 6, 9 and 12
Change From Baseline in Estradiol Levels
Estradiol serum concentration was analyzed centrally. Change from baseline was defined as the value for estradiol levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 3, 6 ,9 and 12
Change From Baseline in Testosterone Levels
Testosterone serum concentration was analyzed centrally. Change from baseline was defined as the value for testosterone levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 3, 6 ,9 and 12
Percentage of Participants With Change From Baseline in Pubertal Stage
Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital stage in male participants, breast stage in female participants and pubic hair stage in both sexes.
Time frame: Baseline (Day 1) and at Months 6 and 12
Percentage of Participants With Stabilized Pubertal Stage Compared to Baseline
Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital stage in male participants, breast stage in female participants and pubic hair stage in both sexes.
Time frame: Baseline (Day 1) and at Months 6 and 12
Change From Baseline in Auxological Parameter: Height
Auxological parameter including height was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 3, 6, 9 and 12
Change From Baseline in Auxological Parameter: Weight
Auxological parameter including weight was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 3, 6, 9 and 12
Change From Baseline in Auxological Parameter: Growth Velocity
Auxological parameter including growth velocity was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 3, 6, 9 and 12
Change From Baseline in Auxological Parameter: Body Mass Index (BMI)
Auxological parameter including BMI was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 3, 6, 9 and 12
Change From Baseline in Bone Age (BA)
BA was determined using X-rays of the hand and wrist. Change from baseline was defined as the value for BA at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 6 and 12
Change From Baseline Difference Between BA and Chronological Age (CA)
BA was determined using X-rays of the hand and wrist. Change from baseline was defined as the difference between BA and CA value at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 6 and 12
Change From Baseline in Uterine Length
Uterine length was determined by type B ultrasound. Change from baseline was defined as the value of uterine length at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 6 and12
Change From Baseline of Testicular Volume
Testicular volume was determined by type B ultrasound. Change from baseline was defined as the value of testicular volume at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
Time frame: Baseline (Day 1) and at Months 6 and 12
This prospective, Phase 3, open-label, single arm, 2-phase (main study phase and an extension phase) study was conducted in children with central precocious puberty (CPP) at 6 investigational sites in China.
| Milestone | All Participants |
|---|---|
| Started | 32 |
| Completed | 30 |
| Not completed | 2 |
| Withdrew: Withdrawal by parent/guardian | 2 |
| Milestone | All Participants |
|---|---|
| Started | 30 |
| Completed | 29 |
| Not completed | 1 |
| Withdrew: Withdrawal by parent/guardian | 1 |
The LH suppression was defined as stimulated peak LH ≤3 International Units/Liter (IU/L). The GnRH stimulation test was performed by using an intravenous (IV) injection of gonadorelin (synthetic GnRH) to stimulate gonadotrophin release and blood samples were collected after the gonadorelin injection for central assessment of serum LH levels.
| percentage of participants | All Participants |
|---|---|
| Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation | 100 (90.8 to 100) |
Basal LH and FSH serum concentrations were analyzed centrally. Change from baseline was defined as the value for LH and FSH levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| IU/L | All Participants |
|---|---|
| LH, Month 3 | -0.6906 ± 1.6417 |
| LH, Month 6 | -0.7411 ± 1.6606 |
| LH, Month 9 | -0.7415 ± 1.6817 |
| LH, Month 12 | -0.9310 ± 1.6367 |
| FSH, Month 3 | -2.3531 ± 1.8079 |
| FSH, Month 6 | -2.2307 ± 1.7445 |
| FSH, Month 9 | -2.0740 ± 1.7979 |
| FSH, Month 12 | -1.9413 ± 1.6996 |
A synthetic GnRH (gonadorelin) was used for gonadotrophin stimulation. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) (±5 minutes at each timepoint) after a single IV injection of gonadorelin. A suppressed LH response to GnRH stimulation test was defined as peak LH ≤3 IU/L among the 4 timepoints T0, T30, T60 and T90).
| percentage of participants | All Participants |
|---|---|
| Month 6 | 93.5 (81.1 to 98.8) |
| Month 12 | 93.5 (81.1 to 98.8) |
A synthetic GnRH was used for gonadotrophin stimulation. Blood samples were collected prior to gonadorelin injection (timepoint T0) and at 30 minutes (T30), 60 minutes (T60) and 90 minutes (T90) (±5 minutes at each timepoint) after a single IV injection of gonadorelin. The FSH response to GnRH stimulation was the peak FSH level among the 4 timepoints (T0, T30, T60 and T90). The LH response to GnRH stimulation test was defined as peak LH ≤3 IU/L among the 4 timepoints T0, T30, T60 and T90). Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| IU/L | All Participants |
|---|---|
| LH, Month 3 | -23.0969 ± 17.9856 |
| LH, Month 6 | -24.3596 ± 17.9180 |
| LH, Month 12 | -23.7221 ± 18.3669 |
| FSH, Month 3 | -11.2757 ± 4.5026 |
| FSH, Month 6 | -11.2536 ± 4.5267 |
| FSH, Month 12 | -10.4701 ± 4.8424 |
Prepubertal sex steroids assessment included estradiol in female participants and testosterone in male participants. Prepubertal sex steroids levels were defined as: estradiol ≤20 picogram (pg)/milliliter (mL) in female participants and testosterone ≤0.3 nanogram (ng)/mL in male participants.
| percentage of participants | All Participants |
|---|---|
| Month 3 | 100 (90.8 to 100) |
| Month 6 | 96.8 (85.6 to 99.8) |
| Month 9 | 90.3 (76.8 to 97.3) |
| Month 12 | 93.5 (81.1 to 98.8) |
Estradiol serum concentration was analyzed centrally. Change from baseline was defined as the value for estradiol levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| pg/mL | All Participants |
|---|---|
| Month 3 | -8.0047 ± 15.6905 |
| Month 6 | -8.3011 ± 15.9093 |
| Month 9 | -7.7458 ± 15.8683 |
| Month 12 | -8.6204 ± 16.1359 |
Testosterone serum concentration was analyzed centrally. Change from baseline was defined as the value for testosterone levels at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| ng/mL | All Participants |
|---|---|
| Month 3 | -1.3650 ± 1.1734 |
| Month 6 | -1.3650 ± 1.1734 |
| Month 9 | -1.3650 ± 1.1734 |
| Month 12 | -1.3650 ± 1.1734 |
Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital stage in male participants, breast stage in female participants and pubic hair stage in both sexes.
| percentage of participants | All Participants |
|---|---|
| Breast development stage for female participants, Month 6, No change | 35.7 |
| Breast development stage for female participants, Month 6, Reduced | 57.1 |
| Breast development stage for female participants, Month 6, Increased | 3.6 |
| Breast development stage for female participants, Month 6, Missing | 3.6 |
| Genital development stage for male participants, Month 6, No change | 33.3 |
| Genital development stage for male participants, Month 6, Reduced | 66.7 |
| Genital development stage for male participants, Month 6, Increased | 0 |
| Genital development stage for male participants, Month 6, Missing | 0 |
| Pubic hair development stage for female participants, Month 6, No change | 96.4 |
| Pubic hair development stage for female participants, Month 6, Reduced | 0 |
| Pubic hair development stage for female participants, Month 6, Increased | 0 |
| Pubic hair development stage for female participants, Month 6, Missing | 3.6 |
| Pubic hair development stage for male participants, Month 6, No change | 66.7 |
| Pubic hair development stage for male participants, Month 6, Reduced | 33.3 |
| Pubic hair development stage for male participants, Month 6, Increased | 0 |
| Pubic hair development stage for male participants, Month 6, Missing | 0 |
| Breast development stage for female participants, Month 12, No change | 39.3 |
| Breast development stage for female participants, Month 12, Reduced | 50.0 |
| Breast development stage for female participants, Month 12, Increased | 3.6 |
| Breast development stage for female participants, Month 12, Missing | 7.1 |
| Genital development stage for male participants, Month 12, No change | 0 |
| Genital development stage for male participants, Month 12, Reduced | 100 |
| Genital development stage for male participants, Month 12, Increased | 0 |
| Genital development stage for male participants, Month 12, Missing | 0 |
| Pubic hair development stage for female participants, Month 12, No change | 82.1 |
| Pubic hair development stage for female participants, Month 12, Reduced | 0 |
| Pubic hair development stage for female participants, Month 12, Increased | 10.7 |
| Pubic hair development stage for female participants, Month 12, Missing | 7.1 |
| Pubic hair development stage for male participants, Month 12, No change | 66.7 |
| Pubic hair development stage for male participants, Month 12, Reduced | 33.3 |
| Pubic hair development stage for male participants, Month 12, Increased | 0 |
| Pubic hair development stage for male participants, Month 12, Missing | 0 |
Pubertal stage parameters were analyzed using Tanner method. Pubertal stage parameters included genital stage in male participants, breast stage in female participants and pubic hair stage in both sexes.
| percentage of participants | All Participants |
|---|---|
| Breast development stage for girls, Month 6 | 92.9 (79.2 to 98.7) |
| Genital development stage for boys, Month 6 | 100 (36.8 to 100.0) |
| Pubic hair development stage for girls, Month 6 | 96.4 (84.1 to 99.8) |
| Pubic hair development stage for boys, Month 6 | 100 (36.8 to 100.0) |
| Breast development stage for girls, Month 12 | 89.3 (74.6 to 97.0) |
| Genital development stage for boys, Month 12 | 100 (36.8 to 100.0) |
| Pubic hair development stage for girls, Month 12 | 82.1 (66.1 to 92.7) |
| Pubic hair development stage for boys, Month 12 | 100 (36.8 to 100.0) |
Auxological parameter including height was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| centimeter (cm) | All Participants |
|---|---|
| Month 3 | 2.24 ± 0.62 |
| Month 6 | 3.55 ± 0.69 |
| Month 9 | 4.63 ± 0.81 |
| Month 12 | 6.54 ± 0.88 |
Auxological parameter including weight was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| kilogram (kg) | All Participants |
|---|---|
| Month 3 | 1.284 ± 1.319 |
| Month 6 | 2.533 ± 1.647 |
| Month 9 | 3.290 ± 1.899 |
| Month 12 | 4.818 ± 2.385 |
Auxological parameter including growth velocity was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| cm/year | All Participants |
|---|---|
| Month 3 | -0.895 ± 3.637 |
| Month 6 | -3.769 ± 2.806 |
| Month 9 | -4.804 ± 2.927 |
| Month 12 | -2.052 ± 3.089 |
Auxological parameter including BMI was analyzed. Change from baseline was defined as the value for each auxological parameter at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| kg/meter square | All Participants |
|---|---|
| Month 3 | 0.142 ± 0.702 |
| Month 6 | 0.470 ± 0.791 |
| Month 9 | 0.585 ± 0.849 |
| Month 12 | 0.895 ± 1.081 |
BA was determined using X-rays of the hand and wrist. Change from baseline was defined as the value for BA at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| years | All Participants |
|---|---|
| Month 6 | 0.233 ± 0.307 |
| Month 12 | 0.586 ± 0.544 |
BA was determined using X-rays of the hand and wrist. Change from baseline was defined as the difference between BA and CA value at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| years | All Participants |
|---|---|
| Month 6 | -0.44 ± 0.53 |
| Month 12 | -0.48 ± 0.57 |
Uterine length was determined by type B ultrasound. Change from baseline was defined as the value of uterine length at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| cm | All Participants |
|---|---|
| Month 6 | -0.4012 ± 0.4391 |
| Month 12 | -0.3771 ± 0.6534 |
Testicular volume was determined by type B ultrasound. Change from baseline was defined as the value of testicular volume at indicated timepoints minus the value at baseline. Baseline was defined as the last non-missing measurement taken prior to the first dose administered.
| mL | All Participants |
|---|---|
| Left, Month 6 | -2.4022 ± 1.7109 |
| Right, Month 6 | -4.7334 ± 4.4222 |
| Left, Month 12 | -2.8840 ± NA |
| Right, Month 12 | -6.7975 ± 6.3958 |
Collected over Treatment-emergent adverse events were reported from the first dose of study treatment (Day 1) up to end of extension phase, a maximum of approximately 368 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | 0/32 (0%) | 2/32 (6.3%) | 27/32 (84.4%) |
| Event | All Participants |
|---|---|
| PneumoniaInfections and infestations | 2/32 |
| Event | All Participants |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 10/32 |
| Abnormal weight gainMetabolism and nutrition disorders | 7/32 |
| BronchitisInfections and infestations | 3/32 |
| OverweightMetabolism and nutrition disorders | 3/32 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 3/32 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/32 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 3/32 |
| TonsillitisInfections and infestations | 2/32 |
| ObesityMetabolism and nutrition disorders | 2/32 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 2/32 |
Intention-To-Treat (ITT) population consisted of all participants who received at least 1 dose of study medication.
| Age, Categorical(Participants) | All Participants |
|---|---|
| <=18 years | 32 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 7.6 ± 0.8 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 29 |
| Male | 3 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| Chinese | 32 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.
Access criteria: Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).
Data sharing details ↗ · vivli.org
Ran from Mar 2021 to primary completion in Feb 2022, 10 months.
Results were first posted in Aug 2024, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin